Form 4: Fennec Pharmaceuticals Director Rosty Raykov Reports Share Acquisition and Disposal
SEC Form 4 Filing
Director Rosty Raykov reports acquiring and disposing of Fennec Pharmaceuticals shares on March 31, 2025, resulting from the release of restriction from shares awarded on March 31, 2023.
Summary
- On March 31, 2025, Rosty Raykov, a director of Fennec Pharmaceuticals Inc., reported a transaction involving the company's common shares.
- Raykov acquired 2,431 shares and disposed of shares at a price of $0.
- Following the reported transaction, Raykov beneficially owns 71,156 common shares directly.
Sentiment
Score: 5
Explanation: The document is a neutral report of share transactions by a company director. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company directors.
Stakeholder Impact
- The transaction may have a minor impact on shareholders as it reflects insider trading activity, but the volume is relatively small.
Key Dates
| Date | Description |
|---|---|
| 03/31/2023 | Date of original share award. |
| 03/31/2025 | Date of transaction (acquisition and disposal of shares). |
| 04/01/2025 | Date of signature for the report. |
Keywords
Fennec Pharmaceuticals, Director, Share Transaction, Beneficial Ownership, SEC Form 4, Raykov, FENC
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.